Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 24, 2006

View Archived Issues

Update on potential of antibiotics in stroke treatment

Diverse clinical studies in metastatic colorectal cancer reported at GCS meeting

European orphan drug status for AS-1411 in renal and pancreatic cancers

ACIP recommends addition of RotaTeq to childhood immunization schedule

Clearance for phase II study of CTA-018 in psoriasis

Positive phase III findings for Desonate HydroGel in atopic dermatitis

Advaxis to start phase I/II testing with Lovaxin C for cervical cancer

Rexahn reviews 2005 milestones

Inspire licenses intranasal epinastine for the U.S. and Canada

Itax international phase III study fails to meet primary endpoint

Biovest requests to use molecular remission data for BiovaxID approval

Preliminary data from R-788 and methotrexate drug interaction study

Oral Telintra studied in phase I/IIa study for MDS

Farnesyltransferase inhibitors for progeria syndromes / News in Context

Cadence to acquire rights to intravenous formulation of acetaminophen

Improved survival in patients receiving DCVax-Brain

Pharmacopeia and Biovitrum collaboration advances new class of compounds

Priority review for Noxafil for prevention of invasive fungal infections

Novelos submits lethal radiation proposal to DHHS

Betaseron sBLA accepted for filing

CombinatoRx discontinues development of CRx-140 for psoriasis

Novel treatment options for inflammatory disorders claimed in recent patents

New patents describe therapeutic agents for respiratory disorders

In vitro activity of new immunomodulator FQPD in multiple myeloma

Positive clinical trial results of tetrabenazine for chorea associated with Huntington's disease

A new synthetic polypeptide may have potential for tissue repair

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...